Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × BI 2536 × Thoracic × Clear all
NCT00376623 2022-06-21

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Boehringer Ingelheim

Phase 2 Completed
96 enrolled 26 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02211833 2014-08-08

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

Boehringer Ingelheim

Phase 1 Completed
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡